Novartis Ianalumab Receives FDA Breakthrough Therapy Designation for Sjogren's Disease
January 17, 2026
January 17, 2026
BASEL, Switzerland, Jan. 17 -- Novartis, a pharmaceutical company, issued the following news release:
* * *
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjogren's disease
* Designation based on clinical evidence supporting potential of ianalumab in Sjogren's disease, including phase III trials1
* Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement o . . .
* * *
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjogren's disease
* Designation based on clinical evidence supporting potential of ianalumab in Sjogren's disease, including phase III trials1
* Distinction expedites development and review of treatments for serious conditions that may demonstrate improvement o . . .